HISTONE DEACETYLASE INHIBITOR INDUCED ANTI-MYELOMA ACTIVITY IS MEDIATED PRINCIPALLY VIA CLASS I DEACETYLASE INHIBITION

被引：0

作者：

Mithraprabhu, S. ^{[1
]}

Kalff, A. ^{[2
]}

Quach, H. ^{[3
]}

Khong, T. ^{[4
]}

Andrew, A. ^{[5
,6
]}

机构：

[1] Monash Univ, Alfred Hlth, Melbourne, Vic, Australia

[2] Alfred Hosp, Malignant Hematol & Stem Cell Transplantat, Melbourne, Vic, Australia

[3] Monash Univ, Dept Clin Hematol, Clayton, Vic, Australia

[4] Monash Univ, Alfred Hosp, Australian Ctr Blood Dis, Melbourne, Vic, Australia

[5] Monash Univ, Alfred Hosp, ACBD, MH&SCT, Melbourne, Vic, Australia

[6] Monash Univ, Alfred Hosp, DCH, Melbourne, Vic, Australia

来源：

HAEMATOLOGICA | 2012年 / 97卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0260

引用

页码：104 / 105

页数：2

共 50 条

[31] Modulation of gene expression profile and in vivo anti-myeloma activity induced by valproic acid, a histone deacytylase inhibitor
Neri, Paola
Calimeri, Teresa
Di Martino, Mariateresa
Rossi, Marco
Eramo, Orietta
Propato, Mariagrazia
Perri, Gino
Pietragalla, Antonella
Ventura, Monica
Bulotta, Alessandra
Blotta, Simona
Tagliaferri, Pierosandro
Anderson, Kenneth C.
Munshi, Nikhil C.
Tassone, Pierfrancesco
BLOOD, 2007, 110 (11) : 271B - 271B
[32] Chromatin Histone Modifying and DNA Repair Inhibition Enhances the Anti-Myeloma Activity of Melphalan
Gkotzamanidou, Maria
Terpos, Evangelos
Munshi, Nikhil C.
Souliotis, Vassilis L.
Dimopoulos, Meletios A.
BLOOD, 2016, 128 (22)
[33] Enhancing the anti-tumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition
Chinnaiyan, P
Varambally, S
Tomlins, SA
Huang, S
Chinnaiyan, AM
Harari, PM
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 202S - 202S
[34] Discovery of a Potent Class I Selective Ketone Histone Deacetylase Inhibitor with Antitumor Activity in Vivo and Optimized Pharmacokinetic Properties
Kinzel, Olaf
Llauger-Bufi, Laura
Pescatore, Giovanna
Rowley, Michael
Schultz-Fademrecht, Carsten
Monteagudo, Edith
Fonsi, Massimiliano
Paz, Odalys Gonzalez
Fiore, Fabrizio
Steinkuehler, Christian
Jones, Philip
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (11) : 3453 - 3456
[35] Total synthesis and biological mode of action of largazole: A potent Class I histone deacetylase inhibitor
Bowers, Albert
West, Nathan
Taunton, Jack
Schreiber, Stuart L.
Bradner, James E.
Williams, Robert M.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2008, 130 (33) : 11219 - 11222
[36] HIV anti-latency treatment mediated by macromolecular prodrugs of histone deacetylase inhibitor, panobinostat
Zuwala, Kaja
Smith, Anton A. A.
Tolstrup, Martin
Zelikin, Alexander N.
CHEMICAL SCIENCE, 2016, 7 (03) : 2353 - 2358
[37] Modular synthesis and biological activity of pyridyl-based analogs of the potent Class I Histone Deacetylase Inhibitor Largazole
Clausen, Dane J.
Smith, William B.
Haines, Brandon E.
Wiest, Olaf
Bradner, James E.
Williams, Robert M.
BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (15) : 5061 - 5074
[38] The Class I Histone Deacetylase Inhibitor MS-275 Prevents Pancreatic Beta Cell Death Induced by Palmitate
Plaisance, Valerie
Rolland, Laure
Gmyr, Valery
Annicotte, Jean-Sebastien
Kerr-Conte, Julie
Pattou, Francois
Abderrahmani, Amar
JOURNAL OF DIABETES RESEARCH, 2014, 2014
[39] The novel histone deacetylase inhibitor OSU-HDAC42 has class I and II histone deacetylase (HDAC) inhibitory activity and represents a novel therapy for chronic lymphocytic leukemia.
West, Derek A.
Lucas, David M.
Davis, Melanie E.
De lay, Michael D.
Johnson, Amy J.
Guster, Sara E.
Freitas, Michael A.
Parthun, Mark R.
Wang, Dasheng
Kulp, Samuel K.
Grever, Michael R.
Chen, Ching-Shih
Byrd, John C.
BLOOD, 2006, 108 (11) : 794A - 795A
[40] Comprehensive analysis of microRNAs modulated by histone deacetylase inhibitors identifies microRNA-7-5p with anti-myeloma effect
Yamada, Masahiro
Ikeda, Sho
Kuroki, Wataru
Iwama, Sayaka
Takahashi, Yuto
Kitadate, Akihiro
Tagawa, Hiroyuki
Takahashi, Naoto
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (03) : 325 - 336

← 1 2 3 4 5 →